Evidence map›Paper›PMID 27252515›Full record

Trial reportHaematologica2016

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Massimo Breccia, Elisabetta Abruzzese, Alessandra Iurlo, Antonella Gozzini, Alessandro Isidori, Domenica Gangemi, Patrizia Pregno, Giuliana Alimena

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Massimo BrecciaDepartment of Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy breccia@bce.uniroma1.it.
Elisabetta AbruzzeseHematology, S.Eugenio Hospital, Rome, Italy.
Alessandra IurloIRCCS Cà Granda Policlinico, Milan, Italy.
Antonella GozziniCareggi Hospital, Florence, Italy.
Alessandro IsidoriDepartment of Hematology, Pesaro, Italy.
Domenica GangemiDepartment of Hematology, Frosinone, Italy.
Patrizia PregnoS.Giovanni Battista Hospital, Turin, Italy.
Giuliana AlimenaDepartment of Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedHumansImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMiddle AgedProtein Kinase InhibitorsPyridazinesImidazolesponatinibProtein Kinase InhibitorsPyridazineschronic myeloid leukemiaponatinibprognosis

Identifiers

PMID27252515
PMCPMC5013958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.